IL164317A0 - Statin therapy for enhancing cognitive maintenance - Google Patents

Statin therapy for enhancing cognitive maintenance

Info

Publication number: IL164317A0
Authority: IL; Israel
Prior art keywords: statin; statin therapy; enhancing cognitive; galantamine; active ingredient
Prior art date: 2002-04-02

Application number

IL16431703A

Other languages

English (en)

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-02

Filing date

2003-03-28

Publication date

2005-12-18

2003-03-28 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2005-12-18 Publication of IL164317A0 publication Critical patent/IL164317A0/xx

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
230000001149 cognitive effect Effects 0.000 title 1
230000002708 enhancing effect Effects 0.000 title 1
238000012423 maintenance Methods 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 4
206010012289 Dementia Diseases 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 2
229960003980 galantamine Drugs 0.000 abstract 2
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)

IL16431703A 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance IL164317A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36928502P	2002-04-02	2002-04-02
PCT/EP2003/003324 WO2003082298A1 (en)	2002-04-02	2003-03-28	Statin therapy for enhancing cognitive maintenance

Publications (1)

Publication Number	Publication Date
IL164317A0 true IL164317A0 (en)	2005-12-18

Family

ID=28675573

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16431703A IL164317A0 (en)	2002-04-02	2003-03-28	Statin therapy for enhancing cognitive maintenance
IL164317A IL164317A (en)	2002-04-02	2004-09-28	Pharmaceutical compositions comprising statin for use in the treatment of patients suffering from memory disorder, and a process for making the same

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL164317A IL164317A (en)	2002-04-02	2004-09-28	Pharmaceutical compositions comprising statin for use in the treatment of patients suffering from memory disorder, and a process for making the same

Country Status (21)

Country	Link
EP (1)	EP1492539B1 (de)
JP (1)	JP2005525391A (de)
KR (1)	KR100986194B1 (de)
CN (1)	CN100528164C (de)
AT (1)	ATE331523T1 (de)
AU (1)	AU2003226753B2 (de)
BR (1)	BR0308293A (de)
CA (1)	CA2480275C (de)
CY (1)	CY1105545T1 (de)
DE (1)	DE60306503T2 (de)
DK (1)	DK1492539T3 (de)
EA (1)	EA013069B1 (de)
ES (1)	ES2268393T3 (de)
IL (2)	IL164317A0 (de)
MX (1)	MXPA04009535A (de)
NO (1)	NO20044698L (de)
NZ (1)	NZ536111A (de)
PL (1)	PL211160B1 (de)
PT (1)	PT1492539E (de)
UA (1)	UA79605C2 (de)
WO (1)	WO2003082298A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004071431A2 (en) *	2003-02-05	2004-08-26	Myriad Genetics, Inc.	Method and composition for treating neurodegenerative disorders
JP2007532624A (ja) *	2004-04-14	2007-11-15	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	アルツハイマー病の治療のための療法組合せ
EP1604686A1 (de) *	2004-06-08	2005-12-14	Axonyx, Inc.	Verwendung von Phenserine und einem HMG CoA reduktase Hemmer zur Verzögerung der Alzheimer Krankheit
GB0607946D0 (en) *	2006-04-21	2006-05-31	Minster Res The Ltd	Mono and combination therapy
US20080103105A1 (en) *	2006-09-22	2008-05-01	Braincells, Inc.	HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
TWI432195B (zh)	2007-10-03	2014-04-01	Kowa Co	神經細胞死亡抑制劑
WO2015089349A1 (en) *	2013-12-13	2015-06-18	Tabaczynski David A	Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW506836B (en) *	1996-06-14	2002-10-21	Janssen Pharmaceutica Nv	Fast-dissolving galanthamine hydrobromide tablet

2003
- 2003-03-28 CN CNB038073854A patent/CN100528164C/zh not_active Expired - Fee Related
- 2003-03-28 EP EP03745196A patent/EP1492539B1/de not_active Expired - Lifetime
- 2003-03-28 MX MXPA04009535A patent/MXPA04009535A/es active IP Right Grant
- 2003-03-28 PL PL371551A patent/PL211160B1/pl unknown
- 2003-03-28 DE DE60306503T patent/DE60306503T2/de not_active Expired - Lifetime
- 2003-03-28 BR BR0308293-8A patent/BR0308293A/pt not_active IP Right Cessation
- 2003-03-28 IL IL16431703A patent/IL164317A0/xx unknown
- 2003-03-28 KR KR1020047013127A patent/KR100986194B1/ko not_active Expired - Fee Related
- 2003-03-28 DK DK03745196T patent/DK1492539T3/da active
- 2003-03-28 JP JP2003579835A patent/JP2005525391A/ja active Pending
- 2003-03-28 AU AU2003226753A patent/AU2003226753B2/en not_active Ceased
- 2003-03-28 EA EA200401295A patent/EA013069B1/ru not_active IP Right Cessation
- 2003-03-28 UA UA20040806803A patent/UA79605C2/uk unknown
- 2003-03-28 ES ES03745196T patent/ES2268393T3/es not_active Expired - Lifetime
- 2003-03-28 WO PCT/EP2003/003324 patent/WO2003082298A1/en not_active Ceased
- 2003-03-28 CA CA2480275A patent/CA2480275C/en not_active Expired - Fee Related
- 2003-03-28 NZ NZ536111A patent/NZ536111A/xx not_active IP Right Cessation
- 2003-03-28 AT AT03745196T patent/ATE331523T1/de active
- 2003-03-28 PT PT03745196T patent/PT1492539E/pt unknown
2004
- 2004-09-28 IL IL164317A patent/IL164317A/en not_active IP Right Cessation
- 2004-10-29 NO NO20044698A patent/NO20044698L/no not_active Application Discontinuation
2006
- 2006-09-27 CY CY20061101397T patent/CY1105545T1/el unknown

Also Published As

Publication number	Publication date
PT1492539E (pt)	2006-11-30
IL164317A (en)	2010-04-29
ES2268393T3 (es)	2007-03-16
NO20044698L (no)	2004-10-29
EA013069B1 (ru)	2010-02-26
CA2480275A1 (en)	2003-10-09
EA200401295A1 (ru)	2005-02-24
CA2480275C (en)	2011-08-16
ATE331523T1 (de)	2006-07-15
MXPA04009535A (es)	2005-01-25
EP1492539A1 (de)	2005-01-05
CN100528164C (zh)	2009-08-19
HK1079688A1 (zh)	2006-04-13
KR20040096608A (ko)	2004-11-16
WO2003082298A1 (en)	2003-10-09
NZ536111A (en)	2006-03-31
KR100986194B1 (ko)	2010-10-07
AU2003226753B2 (en)	2007-06-28
BR0308293A (pt)	2004-12-28
CN1642555A (zh)	2005-07-20
AU2003226753A1 (en)	2003-10-13
EP1492539B1 (de)	2006-06-28
PL211160B1 (pl)	2012-04-30
DE60306503T2 (de)	2007-06-21
DK1492539T3 (da)	2006-10-30
JP2005525391A (ja)	2005-08-25
UA79605C2 (en)	2007-07-10
PL371551A1 (en)	2005-06-27
DE60306503D1 (de)	2006-08-10
CY1105545T1 (el)	2010-07-28

Similar Documents

Publication	Publication Date	Title
DE60126980D1 (de)	2007-04-12	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MXPA05006940A (es)	2006-02-22	Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
DE69713526D1 (de)	2002-07-25	Lösliche prodrugs von paclitaxel
ATE375341T1 (de)	2007-10-15	Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
PL309604A1 (en)	1995-10-30	Pharmaceutical composition for treating nicotin dependence
MXPA05003253A (es)	2005-06-08	Nuevos derivados de pirimidinamida y el uso de los mismos.
MY118526A (en)	2004-11-30	Method for improving the pharmacokinetics of tipranavir
ATE273693T1 (de)	2004-09-15	Proteinhaltige arzneimittel
UA32457C2 (uk)	2000-12-15	Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
BG104179A (en)	2000-10-31	Phanquinon administration for the treatment of the alzheimer's disease
PL371551A1 (en)	2005-06-27	Statin therapy for enhancing cognitive maintenance
GB2331926A (en)	1999-06-09	Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
BG105342A (en)	2001-12-29	Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
TW200633694A (en)	2006-10-01	Composition and method for treating asthma
GEP20053512B (en)	2005-05-10	S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
WO2004030684A3 (en)	2004-09-23	Kavalactone product
TW200700075A (en)	2007-01-01	Roflumilast and integrin inhibitor combination and method of treatment
ATE293445T1 (de)	2005-05-15	Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
NZ268914A (en)	1999-06-29	Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
DE69434002D1 (de)	2004-10-21	2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
UA41326C2 (uk)	2001-09-17	Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
WO2003066806A3 (en)	2003-12-24	Therapeutic use of aziridino compounds